Solution Group Berhad's wholly-owned subsidiary, Solution Biologics Sdn Bhd (SOLBIO) announce that SOLBIO has signed a Memorandum of Understanding (MoU) with National Institutes of Biotechnology Malaysia (NIBM) and CanSino Biologics Inc. (CanSinoBIO) for the collaboration on research and development of human vaccines namely Meningococcal, Dengue, Human Papillomavirus, Hand Foot & Mouth and Zika. The MoU formalises the mutual interaction and strengthens the existing relationship between NIBM, SOLBIO and CanSinoBIO at the strategic and working level, focusing on joint research programs on the development of selected human vaccines, exchange of researchers and technical experts, technology, and knowledge transfer, biomanufacturing, and commercialization of vaccine products for Malaysia and international markets. This MoU provides for continued strengthening of future cooperation between the 3 parties in achieving common goals in providing effective, safe and affordable human vaccines in line with
the aspiration of the Malaysian Vaccine roadmap. This MOU will enhance the SOLBIO capability in vaccine research and manufacturing and in the future will contribute to the Malaysian bio-based economy.